| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Vigil Neuroscience, Inc.
13D/A
VIGL · 92673K108
|
0% |
8/7/2025
Event 8/5/2025
|
||||
| Atlas Venture Fund XII, L.P. | 0% | |||||
| Atlas Venture Associates XII, L.P. | 0% | |||||
| Atlas Venture Associates XII, LLC | 0% | |||||
| Atlas Venture Opportunity Fund I, L.P. | 0% | |||||
| Atlas Venture Associates Opportunity I, L.P. | 0% | |||||
| Atlas Venture Associates Opportunity I, LLC | 0% | |||||
|
Jade Biosciences, Inc.
13D/A
JBIO · 008064206
|
0.2% |
4/30/2025
Event 4/28/2025
|
||||
| Atlas Venture Fund XII, L.P. | 0.2% | |||||
| Atlas Venture Associates XII, L.P. | 0.2% | |||||
| Atlas Venture Associates XII, LLC | 0.2% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.